With Costs At a Decade Low, Ireland Pitches To Indian Companies For Long-term Investments
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Has the global meltdown triggered in 2008 made Europe a competitive destination for investments in manufacturing facilities? That question made rounds amongst a few large Indian pharmaceutical companies as leading executives from the Industrial Development Authority of Ireland pitched to funnel long-term investments from Indian generic drug makers
You may also be interested in...
Daiichi Sankyo Forms Ireland Marketing Subsidiary, Continues European Push
TOKYO - Daiichi Sankyo said Nov. 26 that its German subsidiary, Daiichi Sankyo Europe, has formed a sales subsidiary in Dublin, Ireland for marketing its core products by obtaining Merck Serono's cardiometabolic sales force there
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).